WorldPharmaNews
  • Home
  • Business
  • Research
  • Events
  • Regulatory

Bayer

The Bayer GroupBayer is a global enterprise with core competencies in the fields of health care, agriculture and high-tech polymer materials. As an innovation company, it sets trends in research-intensive areas. Bayer's products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2014, the Group employed 118,900 people and had sales of EUR 42.2 billion. Capital expenditures amounted to EUR 2.5 billion, R&D expenses to EUR 3.6 billion.

www.bayer.com.

Bayer RSS Channel

Filters
List of articles in category Bayer
Title Published Date
Bayer and Ardea Biosciences Enter Global Agreement Focused on the Development of MEK Inhibitors 30 April 2009
Bayer Crop Science and the French research organization CNRS intensify collaboration 31 March 2009
New image of therapy for erectile difficulties 20 March 2009
Advances in Renal Cancer Journalists' Award 27 February 2009
Bayer Schering Pharma to invest 100 million Euro in China to build a global R&D center 12 February 2009
Bayer innovations provide solutions for the global challenges of the future 15 December 2008
Bayer Schering Pharma expands men's healthcare portfolio 05 December 2008
Bayer's Xarelto® Shows Encouraging Results in Patients with Acute Coronary Syndrome 11 November 2008
European Journalists' Prize 2008 announced by Bayer HealthCare 14 October 2008
Bayer Reports Progress in Clinical Program for Riociguat 06 October 2008
Bayer starts new research cooperation in Asia 30 September 2008
Bayer HealthCare acquires German DIREVO Biotech AG 17 September 2008
Bayer Intensifies Research in Early Diagnosis of Alzheimer's Disease 11 September 2008
New low-dose oral contraceptive YAZ® launched in Europe 09 September 2008
Rivaroxaban Phase II Data in ACS to be Presented at AHA Congress in November 01 September 2008
New Trial to Evaluate Nexavar® as Adjuvant Therapy in Liver Cancer 22 August 2008
Nexavar Approved for Treatment of Liver Cancer in China 28 July 2008
Nexavar Study Demonstrates Significant Improvement in Overall Survival 25 July 2008
Bayer concludes supply and licensing agreements for Yasmin® and YAZ® with Barr for the United Stat 24 June 2008
Bayer HealthCare Commits US-Dollar 2.5 Million in Funding to Advance Global Hemophilia Research 04 June 2008
  • Start
  • Prev
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • Next
  • End

Business & Industry

  • Vir Biotechnology and GSK announce NHS-supported AGILE study to evaluate VIR-7832 in the early treatment of COVID-19
  • Bayer transforms pharma business through breakthrough innovation in healthcare
  • Valneva in advanced discussions with European Commission to supply up to 60 million doses of inactivated, adjuvanted COVID-19 vaccine candidate
  • An in vitro study shows Pfizer-BioNTech COVID-19 vaccine elicits antibodies that neutralize SARS-CoV-2 with a mutation associated with rapid transmission
  • European Commission authorizes COVID-19 vaccine Moderna in Europe

Research & Development

  • New England Journal of Medicine publishes COVID-19 treatment trial results
  • Scientists identify 'immune cop' that detects SARS-CoV-2
  • New findings help explain how COVID-19 overpowers the immune system
  • New virtual screening strategy identifies existing drug that inhibits COVID-19 virus
  • Sustained cellular immune dysregulation in individuals recovering from COVID-19
  • How SARS-CoV-2 interacts with cells
  • Neutralizing antibodies protect against severe COVID-19

Conferences & Events

  • CPhI Worldwide to return in 2021
  • Reuters Events' Cell & Gene Therapy USA
  • Total health: Build a better healthcare system
  • Don't fall for the 'next best action' trap
  • Locking down shape-shifting spike protein aids development of COVID-19 vaccine
  • COVID-19 vaccine innovation could dramatically speed up worldwide production
  • Wearable Injectors and Connected Devices Conference 2020

Regulatory Affairs

  • EMA receives application for conditional marketing authorisation of COVID-19 Vaccine AstraZeneca
  • FDA takes additional action in fight against COVID-19 by issuing Emergency Use Authorization for second COVID-19 vaccine
  • Update on assessment of the BioNTech and Pfizer BNT162b2 vaccine marketing authorisation application
  • FDA takes key action in fight against COVID-19 by issuing Emergency Use Authorization for first COVID-19 vaccine
  • EMA receives application for conditional marketing authorisation of COVID-19 mRNA vaccine BNT162b2
  1. You are here:  
  2. Home
  3. Bayer
  4. Bayer is taking collaboration with health care start-ups to the next level

About

  • Home
  • Advertise
  • Privacy
  • Terms of Use
  • Contact

Top News Channels

  • Industry
  • Research
  • Regulatory

Submit Your News!

Follow / Join us

Didn't we got you connected? If not, please note the following magic buttons:
  • Facebook
  • Twitter
  • LinkedIn
  • XING
  • RSS

Digest World Pharma Newsletter

Subscribe to our weekly Digest Newsletter and stay updated on the latest World Pharma News. Subscribe now, it's free!

© World Pharma News 2021. All Rights Reserved.